Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial (vol 11, pg 611, 2009)

被引：0
|
作者：
Jadzinsky, M.
Pfuetzner, A.
Paz-Pacheco, F.
Xu, Z.
Allen, F.
Chen, R.
机构：
来源：
DIABETES OBESITY & METABOLISM | 2010年 / 12卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：462 / 462
页数：1
相关论文
共 50 条
  • [41] A randomized controlled clinical trial of combination therapy for type 2 diabetes by vildagliptin, metformin, and α-glucosidase inhibitor
    Wang, Qiong
    Su, Yong
    Lv, Lifang
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2016, 36 (04) : 420 - 425
  • [42] Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
    Williams-Herman, D.
    Johnson, J.
    Teng, R.
    Golm, G.
    Kaufman, K. D.
    Goldstein, B. J.
    Amatruda, J. M.
    DIABETES OBESITY & METABOLISM, 2010, 12 (05): : 442 - 451
  • [43] The effect of periodontal therapy on glycaemic control in a Hispanic population with type 2 diabetes: a randomized controlled trial
    Gay, Isabel C.
    Tran, Duong T.
    Cavender, Adriana C.
    Weltman, Robin
    Chang, Jennifer
    Luckenbach, Estelle
    Tribble, Gena D.
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2014, 41 (07) : 673 - 680
  • [44] Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
    Kovacs, C. S.
    Seshiah, V.
    Swallow, R.
    Jones, R.
    Rattunde, H.
    Woerle, H. J.
    Broedl, U. C.
    DIABETES OBESITY & METABOLISM, 2014, 16 (02): : 147 - 158
  • [45] Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
    Bosi, E.
    Dotta, F.
    Jia, Y.
    Goodman, M.
    DIABETES OBESITY & METABOLISM, 2009, 11 (05): : 506 - 515
  • [46] Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control
    Rosenstock, J.
    Rood, J.
    Cobitz, A.
    Huang, C.
    Garber, A.
    DIABETES OBESITY & METABOLISM, 2006, 8 (06): : 643 - 649
  • [47] Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care
    Cook, M. N.
    Girman, C. J.
    Stein, P. P.
    Alexander, C. M.
    DIABETIC MEDICINE, 2007, 24 (04) : 350 - 358
  • [48] Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
    Rosenstock, J.
    Baron, M. A.
    Camisasca, R. -P.
    Cressier, F.
    Couturier, A.
    Dejager, S.
    DIABETES OBESITY & METABOLISM, 2007, 9 (02): : 175 - 185
  • [49] A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus
    Su, Yong
    Su, Ya-Li
    Lv, Li-Fang
    Wang, Li-Min
    Li, Quan-Zhong
    Zhao, Zhi-Gang
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 7 (04) : 799 - 803
  • [50] Initial Treatment with Sitagliptin as Monotherapy or Combination Therapy Improves Markers of β-Cell Function in Patients with Type 2 Diabetes
    Steinberg, Helmut
    Engel, Samuel S.
    Golm, Gregory T.
    Alba, Maria
    Langdon, Ronald B.
    Kaufman, Keith D.
    Goldstein, Barry J.
    DIABETES, 2011, 60 : A610 - A610
12345